Saturday 17 October 2026 Export CVKD’s income statement to Excel — free account

Cadrenal Therapeutics, Inc.

In the quarter to June 2026, EPS grew 39.0% and free cash flow grew 26.2%, each against the same quarter a year earlier.

1.09 0.12 +12.37%

Follow CVKD

Alert me

Market cap: $3.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.46

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	3	7	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 3.46

Revenue —

Net Income (11.54)

Free Cash Flow (10.16)

Net Debt (2.39)

Current Ratio 3.73

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.78

Past 5Y EPS Growth —

This Y EPS Growth 41.82%

Next Y EPS Growth 22.17%

Next Y revenue growth —

Next 5Y EPS Growth 34.69%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 3.37%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	10	4	2
Receivables	0	0	0	3
Inventory	—	—	—	—
Other	—	—	—	—
	8	10	4	6

	2023	2024	2025	Q'26
Payables	0	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	3	2	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	—	0.00%
Book Value	—	—	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(5)	(3)	(2)	(3)	(13)
’24	(2)	(2)	(2)	(2)	(7)
’23	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(5)	(3)	(2)	(3)	(13)
’24	(2)	(2)	(2)	(2)	(7)
’23	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.04)	(1.14)	—	—	—
’25	(2.09)	(1.87)	(1.31)	(1.41)	(6.64)
’24	(1.50)	(2.25)	(2.18)	(2.74)	(8.73)
’23	(7.20)	(1.35)	(1.05)	(0.75)	(9.30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	5.93	5.40	6.42	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	101.25	32.55	22.90
People
People	Employees	—	—	—	—	—	—	3	4	4	5
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	0.00	—	—	—
	EBT	—	—	—	—	—	—	(7)	(8)	(11)	(13)
	EBT margin, %	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	—	—	(7)	(8)	(11)	(13)
	Depreciation	—	—	—	—	—	—	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	—	(12.76)	(9.30)	(8.73)	(6.64)
	Cash flow	—	—	—	—	—	—	(2.29)	(3.92)	(6.03)	(6.32)
	Capex	—	—	—	—	—	—	0.00	0.00	(0.01)	0.00
	Free cash flow	—	—	—	—	—	—	(2.29)	(3.93)	(6.04)	(6.32)
	Book value	—	—	—	—	—	—	(10.55)	8.55	6.10	1.37
	Shares, m	—	—	—	—	—	—	1	1	1	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	—	(1)	(4)	(7)	(13)
	Capex	—	—	—	—	—	—	0	0	0	0
	Free cash flow	—	—	—	—	—	—	(1)	(4)	(7)	(13)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	—	(1)	8	7	3
	Total debt	—	—	—	—	—	—	1	—	—	—
	Net debt	—	—	—	—	—	—	1	(8)	(10)	(4)
	Shareholders’ equity	—	—	—	—	—	—	(6)	8	7	3
Returns, %
Returns, %	ROA	—	—	—	—	—	—	0.00	(179.77)	(114.27)	(183.21)
	ROIC	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	—	0.00	(780.60)	(140.78)	(260.11)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KALA KALA BIO, Inc.	$3.7M	— (loss-making)	— (loss-making)	−86.31% (below 0%: shrinking)	n/m	+80.19% (above 0%: growing)	0.00%	0.00%	Compare
ERNA Ernexa Therapeutics Inc.	$3.5M	— (loss-making)	— (loss-making)	−94.12% (below 0%: shrinking)	n/m	−64.10% (below 0%: shrinking)	100.00%	0.00%	Compare
PPCB Propanc Biopharma Inc	$3.5M	— (loss-making)	—	—	−99.64% (below 0%: shrinking)	−1,637.42% (below 0%: shrinking)	—	0.00%	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.5M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%
IOBTQ IO Biotech, Inc.	$3.5M	— (loss-making)	—	—	n/m	+11.22% (above 0%: growing)	0.00%	0.00%	Compare
UNBX UNITY Biotechnology, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	−23.10% (below 0%: shrinking)	0.00%	0.00%	Compare
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
PBLA Panbela Therapeutics Inc.	$3.4M	— (loss-making)	—	—	n/m	+66.23% (above 0%: growing)	—	0.00%	Compare
CMND Clearmind Medicine Inc.	$3.3M	— (loss-making)	—	—	n/m	−77.94% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$3.4M	—	—	−86.31%	—	−32.44%	0.00%	0.00%

All 614 Biotechnology stocks →

Cadrenal Therapeutics, Inc. (CVKD) key facts

Cadrenal Therapeutics, Inc. (CVKD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CVKD traded at $1.09, a market capitalization of $3.5 million.
Return on equity was −260.1% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.